DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
EW logo

Edwards Lifesciences Corporation Stock Price

NYSE:EW Community·US$49.7b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 72 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

EW Share Price Performance

US$86.77
8.76 (11.23%)
​
US$100.96
Fair Value
US$86.77
8.76 (11.23%)
14.1% undervalued intrinsic discount
US$100.96
Fair Value
Price US$86.77
AnalystConsensusTarget US$100.96
Thu, 30 Jul 26
Fair ValueUS$100.96
Share Pricen/a

EW Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$100.96 14.1% undervalued intrinsic discount

Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead

0users have liked this narrative
0users have commented on this narrative
27users have followed this narrative
EW logo
Edwards Lifesciences
14.1% undervalued intrinsic discount

Durability Data And Real-World Evidence Will Shape Risk And Opportunity Ahead

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 30 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
EW logo

EW: CMS TAVR Policy Shift Will Extend Structural Heart Upside

Fair Value: US$100.96 14.1% undervalued intrinsic discount
27 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Flawless balance sheet with moderate growth potential.

2 Risks
2 Rewards
View Full Analysis

Edwards Lifesciences Corporation Key Details

US$6.5b

Revenue

US$1.4b

Cost of Revenue

US$5.1b

Gross Profit

US$4.1b

Other Expenses

US$979.9m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
1.70
77.84%
15.05%
5.6%
View Full Analysis

About EW

Founded
1958
Employees
16000
CEO
Bernard Zovighian
WebsiteView website
www.edwards.com

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Recent EW News & Updates

Seeking Alpha • Sep 07

Edwards Lifesciences: $20 Billion TAM And A Meaningful Opportunity To Compound

Summary We initiated a position in Edwards Lifesciences Corporation, a leading manufacturer of heart valve replacement and repair products. We believe that today's $7 billion market for TAVR can grow to more than $10 billion as approved indications expand to allow TAVR to cover a broader patient population. Addressing TMTT issues is structurally much more complex than TAVR, and the barrier to developing effective solutions is extremely high. The company also has an attractive and improving margin structure, with 78% gross margins and 27% operating margins. Read the full article on Seeking Alpha

Recent updates

No updates

Edwards Lifesciences Corporation Competitors

UNH logo

UnitedHealth Group

Symbol: NYSE:UNH
Market cap: US$352.8b
ABT logo

Abbott Laboratories

Symbol: NYSE:ABT
Market cap: US$182.1b
ISRG logo

Intuitive Surgical

Symbol: NasdaqGS:ISRG
Market cap: US$124.8b
CVS logo

CVS Health

Symbol: NYSE:CVS
Market cap: US$122.0b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide